Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743674 · ClinicalTrials.gov registry record
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
A clinical trial of Cervical Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 30
- Enrollment target
- 2
- Study locations
NCT04743674 is a study of Cervical Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04743674, a study of Cervical Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.
Conditions Studied
Study Locations (2)
North Carolina
- Melissa Knutsen - Chapel Hill
Other
- Kamuzu Central Hospital - Lilongwe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-03 |
| Est. Completion | 2027-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04743674
The ClinicalTrials.gov registry entry for NCT04743674 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04743674 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT04743674 about?
NCT04743674 is a clinical study titled "Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment". The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of ce...
What is the current status of trial NCT04743674?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-05-03. Estimated completion is 2027-01-15.
What conditions does trial NCT04743674 study?
This clinical trial studies the following conditions: Cervical Cancer.
Who is sponsoring clinical trial NCT04743674?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04743674 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.